Understand the source comparison
Pe-22-28 for Anxiety: Preclinical Comparison Table
| Compound | Primary Mechanism | Onset of Anxiolytic Effect | Sedation / Cognitive Impairment | Neuroplasticity Effects | Clinical Status | Professional Assessment ||—|—|—|—|—|—|| Pe-22-28 | Neuroinflammation modulation, BDNF upregulation, NMDA normalization |
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Compound | Primary Mechanism | Onset of Anxiolytic Effect | Sedation / Cognitive Impairment | Neuroplasticity Effects | Clinical Status | Professional Assessment ||—|—|—|—|—|—|| Pe-22-28 | Neuroinflammation modulation, BDNF upregulation, NMDA normalization | 7–10 days (rodent models) | None observed at therapeutic doses | Sustained increase in hippocampal neurogenesis and synaptic plasticity | Research compound only—no human trials | Compelling preclinical data but lacks clinical validation. Useful for dissecting neuroinflammation's role in anxiety. || Diazepam (Benzodiazepine) | GABAa receptor positive allosteric modulation | 20–30 minutes | Significant sedation, motor impairment, cognitive dulling | None—may inhibit neurogenesis chronically | FDA-approved for anxiety, decades of clinical use | Highly effective for acute anxiety but unsuitable for long-term use due to dependence and tolerance. || Fluoxetine (SSRI) | Serotonin reuptake inhibition | 4–8 weeks | Minimal sedation; emoti
- This table reflects preclinical and clinical data available as of 2026. Pe-22-28's lack of human trials is the critical limitation—everything we know about its anxiolytic potential comes from rodent behavioral models and in vitro mechanistic studies. The absence of human pharmacokinetic data, safety profiles, and dose-response curves means it remains a laboratory research tool rather than a therapeutic option.